<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ATOVAQUONE AND PROGUANIL HYDROCHLORIDE - atovaquone and proguanil hydrochloride tablet, film coated </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1>Atovaquone and Proguanil Hydrochloride Tablets </h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_394bc5ea-bf39-4fa1-aa21-ee849f87a095"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_d94ba27e-e406-4e95-9f25-6bd7b8f83954"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Atovaquone and proguanil hydrochloride is a fixed-dose combination of the antimalarial agents atovaquone and proguanil hydrochloride. The chemical name of atovaquone is <span class="Italics">trans</span>-2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthalenedione. Atovaquone is a yellow crystalline solid that is practically insoluble in water. It has a molecular weight of 366.84 and the molecular formula C<span class="Sub">22</span>H<span class="Sub">19</span>ClO<span class="Sub">3</span>. The compound has the following structural formula: </p>
<div class="Figure">
<a name="id299"></a><img alt="Structural Formula for Atovaquone" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c50d51ab-23c2-45cb-8f68-08f3454fb59b&amp;name=b876b25a-ab9b-4e58-95a8-3edc2a3ee69a-01.jpg">
</div>
<p>The chemical name of proguanil hydrochloride USP is 1-(4-chlorophenyl)-5-isopropyl-biguanide hydrochloride. Proguanil hydrochloride USP is a white crystalline solid that is sparingly soluble in water. It has a molecular weight of 290.22 and the molecular formula C<span class="Sub">11</span>H<span class="Sub">16</span>ClN<span class="Sub">5</span>•HCl. The compound has the following structural formula: </p>
<div class="Figure">
<a name="id305"></a><img alt="Structural Formula for Proguanil HCl" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c50d51ab-23c2-45cb-8f68-08f3454fb59b&amp;name=b876b25a-ab9b-4e58-95a8-3edc2a3ee69a-02.jpg">
</div>
<p>Atovaquone and proguanil hydrochloride tablets are for oral administration. Each atovaquone and proguanil hydrochloride tablet contains 250 mg of atovaquone and 100 mg of proguanil hydrochloride USP.  The inactive ingredients in the tablet are colloidal silicon dioxide, ferric oxide red, hypromellose 2910, low substituted hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, poloxamer 188, povidone K30, polyethylene glycol 400, polyethylene glycol 8000, sodium starch glycolate, titanium dioxide. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_a8ff8a2f-b403-4442-ab2a-72b24e2d1e23"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_358c9c45-c6c6-488b-bb01-4602403f1590"></a><a name="section-3.1"></a><p></p>
<h2>Microbiology:</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_51ead136-c2d8-4f39-a4de-93f8a8962491"></a><a name="section-3.1.1"></a><p></p>
<h3>Mechanism of Action:</h3>
<p class="First">The constituents of atovaquone and proguanil hydrochloride interfere with 2 different pathways involved in the biosynthesis of pyrimidines required for nucleic acid replication. Atovaquone is a selective inhibitor of parasite mitochondrial electron transport. Proguanil hydrochloride primarily exerts its effect by means of the metabolite cycloguanil, a dihydrofolate reductase inhibitor. Inhibition of dihydrofolate reductase in the <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> parasite disrupts deoxythymidylate synthesis. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9a73710d-f450-4663-bf2c-2cb903a995f2"></a><a name="section-3.1.2"></a><p></p>
<h3>Activity In Vitro and In Vivo:  </h3>
<p class="First">Atovaquone and cycloguanil (an active metabolite of proguanil) are active against the erythrocytic and exoerythrocytic stages of <span class="Italics">Plasmodium</span> spp. Enhanced efficacy of the combination compared to either atovaquone or proguanil hydrochloride alone was demonstrated in clinical studies in both immune and non-immune patients (see <span class="Bold"><a href="#i4i_clinical_studies_id_bd56a754-da82-4431-8a36-0e09cc96d52e">CLINICAL STUDIES</a></span>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_645afbf2-c645-4742-aa3f-21876c487b2c"></a><a name="section-3.1.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">Drug Resistance</span>: </h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strains</span> of <span class="Italics">P. falciparum</span> with decreased susceptibility to atovaquone or proguanil/cycloguanil alone can be selected in vitro or in vivo. The combination of atovaquone and proguanil hydrochloride may not be effective for treatment of recrudescent <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> that develops after prior therapy with the combination. </p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_a70493db-272f-4924-9db3-6c2fcb02d0ae"></a><a name="section-3.2"></a><p></p>
<h2>Pharmacokinetics:</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_da66895e-1730-46ca-b3a5-26a5484f38e3"></a><a name="section-3.2.1"></a><p></p>
<h3>Absorption: </h3>
<p class="First">Atovaquone is a highly lipophilic compound with low aqueous solubility. The bioavailability of atovaquone shows considerable inter-individual variability. </p>
<p>Dietary fat taken with atovaquone increases the rate and extent of absorption, increasing AUC 2 to 3 times and Cmax 5 times over fasting. The absolute bioavailability of the tablet formulation of atovaquone when taken with food is 23%. Atovaquone and proguanil hydrochloride tablets should be taken with food or a milky drink. </p>
<p>Proguanil hydrochloride is extensively absorbed regardless of food intake. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cc5c7254-500c-42fc-b079-3ef87e50f743"></a><a name="section-3.2.2"></a><p></p>
<h3>Distribution:  </h3>
<p class="First">Atovaquone is highly protein bound (&gt;99%) over the concentration range of 1 to 90 mcg/mL. A population pharmacokinetic analysis demonstrated that the apparent volume of distribution of atovaquone (V/F) in adult and pediatric patients after oral administration is approximately 8.8 L/kg.</p>
<p>Proguanil is 75% protein bound. A population pharmacokinetic analysis demonstrated that the apparent V/F of proguanil in adult and pediatric patients &gt;15 years of age with body weights from 31 to 110 kg ranged from 1,617 to 2,502 L. In pediatric patients’ ≤15 years of age with body weights from 11 to 56 kg, the V/F of proguanil ranged from 462 to 966 L. </p>
<p>In human plasma, the binding of atovaquone and proguanil was unaffected by the presence of the other. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f232563f-8487-4926-941f-b9ccadcb1672"></a><a name="section-3.2.3"></a><p></p>
<h3>Metabolism:  </h3>
<p class="First">In a study where <span class="Sup">14</span>C-labeled atovaquone was administered to healthy volunteers, greater than 94% of the dose was recovered as unchanged atovaquone in the feces over 21 days. There was little or no excretion of atovaquone in the urine (less than 0.6%). There is indirect evidence that atovaquone may undergo limited metabolism; however, a specific metabolite has not been identified. Between 40% to 60% of proguanil is excreted by the kidneys. Proguanil is metabolized to cycloguanil (primarily via CYP2C19) and 4-chlorophenylbiguanide. The main routes of elimination are hepatic biotransformation and renal excretion. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b5c105c4-72e1-4ecc-85b8-f15364c72817"></a><a name="section-3.2.4"></a><p></p>
<h3>Elimination:  </h3>
<p class="First">The elimination half-life of atovaquone is about 2 to 3 days in adult patients.The elimination half-life of proguanil is 12 to 21 hours in both adult patients and pediatric patients, but may be longer in individuals who are slow metabolizers.</p>
<p>A population pharmacokinetic analysis in adult and pediatric patients showed that the apparent clearance (CL/F) of both atovaquone and proguanil are related to the body weight. The values CL/F for both atovaquone and proguanil in subjects with body weight ≥11 kg are shown in Table 1. </p>
<a name="_RefID849FE8C749044AECABEF0BBDB19B8BB7"></a><table>
<caption><span>Table 1. Apparent Clearance for Atovaquone and Proguanil in Patients as a Function of Body Weight </span></caption>
<col width="16%">
<col width="6%">
<col width="36%">
<col width="6%">
<col width="36%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2"><p class="First">Body Weight</p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2"><p class="First">Atovaquone</p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2"><p class="First">Proguanil</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">N</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">CL/F (L/hr) Mean ± SD* (range)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">N</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">CL/F (L/hr) Mean ± SD (range)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">11-20 Kg</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">159</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">1.34 ± 0.63 (0.52-4.26)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">146</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">29.5 ± 6.5 (10.3-48.3)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">21-30 Kg</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">117</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">1.87 ± 0.81 (0.52-5.38)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">113</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">40.0 ± 7.5 (15.9-62.7)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">31-40 Kg</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">95</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">2.76 ± 2.07 (0.97-12.5)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">91</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">49.5 ± 8.30 (25.8-71.5)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">&gt; 40 Kg</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">368</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">6.61 ± 3.92 (1.32-20.3)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">282</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">67.9 ± 19.9 (14.0 - 145)</p></td>
</tr>
</tbody>
</table>
<p>The pharmacokinetics of atovaquone and proguanil in patients with body weight below 11 kg have not been adequately characterized.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_80121c9e-1582-4ded-932f-789aa6d7d1da"></a><a name="section-3.2.5"></a><p></p>
<h3>Special Populations:</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f12482a1-87e5-4ffd-92b7-cc15655d00ea"></a><a name="section-3.2.5.1"></a><p></p>
<h4>Pediatrics: </h4>
<p class="First">The pharmacokinetics of proguanil and cycloguanil are similar in adult patients and pediatric patients. However, the elimination half-life of atovaquone is shorter in pediatric patients (1 to 2 days) than in adult patients (2 to 3 days). In clinical trials, plasma trough levels of atovaquone and proguanil in pediatric patients weighing 5 to 40 kg were within the range observed in adults after dosing by body weight. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6e121914-d5b5-4f12-9361-54a76af98693"></a><a name="section-3.2.5.2"></a><p></p>
<h4>Geriatrics: </h4>
<p class="First">In a single-dose study, the pharmacokinetics of atovaquone, proguanil, and cycloguanil were compared in 13 elderly subjects (age 65 to 79 years) to 13 younger subjects (age 30 to 45 years). In the elderly subjects, the extent of systemic exposure (AUC) of cycloguanil was increased (point estimate = 2.36, CI = 1.70, 3.28). T<span class="Sub">max</span> was longer in elderly subjects (median 8 hours) compared with younger subjects (median 4 hours) and average elimination half-life was longer in elderly subjects (mean 14.9 hours) compared with younger subjects (mean 8.3 hours). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f413b338-49cf-4fdf-8bd9-55ad2fd8a215"></a><a name="section-3.2.5.3"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: </h4>
<p class="First">In a single-dose study, the pharmacokinetics of atovaquone, proguanil, and cycloguanil were compared in 13 subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (9 mild, 4 moderate, as indicated by the Child-Pugh method) to 13 subjects with normal hepatic function. In subjects with mild or moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> as compared to healthy subjects, there were no marked differences (&lt;50%) in the rate or extent of systemic exposure of atovaquone. However, in subjects with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, the elimination half-life of atovaquone was increased (point estimate = 1.28, 90% CI = 1.00 to 1.63). Proguanil AUC, C<span class="Sub">max</span>, and its t<span class="Sub">1/2</span> increased in subjects with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> when compared to healthy subjects (Table 2). Also, the proguanil AUC and its t<span class="Sub">1/2</span> increased in subjects with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> when compared to healthy subjects. Consistent with the increase in proguanil AUC, there were marked decreases in the systemic exposure of cycloguanil (C<span class="Sub">max</span> and AUC) and an increase in its elimination half-life in subjects with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> when compared to healthy volunteers (Table 2). There were few measurable cycloguanil concentrations in subjects with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (see <span class="Bold"><a href="#i4i_dosage_admin_id_11be0602-fd6d-4814-a137-2f7afc8602a4">DOSAGE AND ADMINISTRATION</a></span>). The pharmacokinetics of atovaquone, proguanil, and cycloguanil after administration of a tovaquone and proguanil hydrochloride have not been studied in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. </p>
<a name="_RefID58B97B7E729E466E94676B3897C59B19"></a><table>
<caption><span>Table 2. Point Estimates (90% CI) for Proguanil and Cycloguanil Parameters in Subjects With Mild and Moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> Compared to Healthy Volunteers </span></caption>
<col width="18%">
<col width="29%">
<col width="26%">
<col width="26%">
<tfoot>
<tr class="First Last"><td class="Botrule" align="left" colspan="4" valign="top">ND = not determined due to lack of quantifiable data.</td></tr>
<tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Ratio of geometric means.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Mean difference. </dd>
</dl></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Toprule"><p class="First">Parameter</p></td>
<td class="Lrule Toprule"><p class="First">Comparison</p></td>
<td class="Lrule Toprule"><p class="First">Proguanil</p></td>
<td class="Toprule"><p class="First">Cycloguanil</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">AUC <span class="Sub">(0-inf)</span></p></td>
<td class="Lrule"><p class="First">mild : healthy</p></td>
<td class="Lrule"><p class="First">1.96 (1.51, 2.54)</p></td>
<td><p class="First">0.32 (0.22, 0.45)</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">C<span class="Sub">max</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td class="Lrule"><p class="First">mild : healthy</p></td>
<td class="Lrule"><p class="First">1.41 (1.16, 1.71)</p></td>
<td><p class="First">0.35 (0.24, 0.50)</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">T 1/2<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a></p></td>
<td class="Lrule"><p class="First">mild : healthy</p></td>
<td class="Lrule"><p class="First">1.21 (0.92, 1.60)</p></td>
<td><p class="First">0.86 (0.49, 1.48)</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">AUC <span class="Sub">(0-inf)</span><a href="#footnote-1" class="Sup">*</a></p></td>
<td class="Lrule"><p class="First">moderate : healthy</p></td>
<td class="Lrule"><p class="First">1.64 (1.14, 2.34)</p></td>
<td><p class="First">ND</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">C<span class="Sub">max</span><a href="#footnote-1" class="Sup">*</a></p></td>
<td class="Lrule"><p class="First">moderate : healthy</p></td>
<td class="Lrule"><p class="First">0.97 (0.69, 1.36)</p></td>
<td><p class="First">ND</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">T 1/2<a href="#footnote-2" class="Sup">†</a></p></td>
<td class="Botrule Lrule"><p class="First">moderate : healthy</p></td>
<td class="Botrule Lrule"><p class="First">1.46 (1.05, 2.05)</p></td>
<td class="Botrule"><p class="First">ND</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5611f0ee-4722-4301-9db6-c57513251345"></a><a name="section-3.2.5.4"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: </h4>
<p class="First">In patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance 50 to 80 mL/min), oral clearance and/or AUC data for atovaquone, proguanil, and cycloguanil are within the range of values observed in patients with normal renal function (creatinine clearance &gt;80 mL/min). In patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance 30 to 50 mL/min), mean oral clearance for proguanil was reduced by approximately 35% compared with patients with normal renal function (creatinine clearance &gt;80 mL/min) and the oral clearance of atovaquone was comparable between patients with normal renal function and mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. No data exist on the use of atovaquone and proguanil hydrochloride for long-term prophylaxis (over 2 months) in individuals with moderate <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>. In patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance &lt;30 mL/min), atovaquone C<span class="Sub">max</span> and AUC are reduced but the elimination half-lives for proguanil and cycloguanil are prolonged, with corresponding increases in AUC, resulting in the potential of drug accumulation and toxicity with repeated dosing (see <span class="Bold"><a href="#i4i_contraindications_id_1908e77c-6a9e-4550-af6c-96a93711b14e">CONTRAINDICATIONS</a></span>). </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d8e2bdac-c44a-4a4b-91c0-b0c021e152f0"></a><a name="section-3.2.6"></a><p></p>
<h3>Drug Interactions:</h3>
<p class="First">There are no <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> between atovaquone and proguanil at the recommended dose. </p>
<p>Concomitant treatment with <span class="Bold">tetracycline</span> has been associated with approximately a 40% reduction in plasma concentrations of atovaquone. </p>
<p>Concomitant treatment with <span class="Bold">metoclopramide</span> has also been associated with decreased bioavailability of atovaquone. </p>
<p>Concomitant administration of <span class="Bold">rifampin</span> or <span class="Bold">rifabutin</span> is known to reduce atovaquone levels by approximately 50% and 34%, respectively (see <span class="Bold"><a href="#i4i_drug_interaction_id_689f4f71-356c-43cf-9afd-9f4375ab3ac9">PRECAUTIONS: Drug Interactions</a></span>). The mechanisms of these interactions are unknown. </p>
<p>Concomitant administration of atovaquone (750 mg BID with food for 14 days) and indinavir (800 mg TID without food for 14 days) did not result in any change in the steady-state AUC and C<span class="Sub">max</span> of indinavir but resulted in a decrease in the C<span class="Sub">trough</span> of indinavir (23% decrease [90% CI 8%, 35%]). Caution should be exercised when prescribing atovaquone with indinavir due to the decrease in trough levels of indinavir.</p>
<p>Atovaquone is highly protein bound (&gt;99%) but does not displace other highly protein-bound drugs in vitro, indicating significant drug interactions arising from displacement are unlikely (see <span class="Bold"><a href="#i4i_drug_interaction_id_689f4f71-356c-43cf-9afd-9f4375ab3ac9">PRECAUTIONS: Drug Interactions</a></span>). Proguanil is metabolized primarily by CYP2C19. Potential <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> with other substrates or inhibitors of this pathway are unknown. </p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_aa83c9f4-5576-49bd-b0cf-2773465d121a"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_46315401-cdfc-4ae1-ade8-b0c825f5c8e9"></a><a name="section-4.1"></a><p></p>
<h2>Prevention of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span>:</h2>
<p class="First">Atovaquone and proguanil hydrochloride tablets are indicated for the prophylaxis of <span class="Italics">P. falciparum</span> <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>, including in areas where chloroquine resistance has been reported (see <span class="Bold"><a href="#i4i_clinical_studies_id_bd56a754-da82-4431-8a36-0e09cc96d52e">CLINICAL STUDIES</a></span>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d9498cba-9891-4ae7-8496-093985698bc6"></a><a name="section-4.2"></a><p></p>
<h2>Treatment of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span>:</h2>
<p class="First">Atovaquone and proguanil hydrochloride tablets are indicated for the treatment of acute, uncomplicated P<span class="Italics">. falciparum</span> <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>. Atovaquone and proguanil hydrochloride tablets have been shown to be effective in regions where the drugs chloroquine, halofantrine, mefloquine, and amodiaquine may have unacceptable failure rates, presumably due to <span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_1908e77c-6a9e-4550-af6c-96a93711b14e"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS </h1>
<p class="First">Atovaquone and proguanil hydrochloride is contraindicated in individuals with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to atovaquone or proguanil hydrochloride or any component of the formulation. Rare cases of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> following treatment with atovaquone/proguanil have been reported. </p>
<p>Atovaquone and proguanil hydrochloride is contraindicated for prophylaxis of <span class="Italics">P. falciparum</span> <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance &lt;30 mL/min) (see <span class="Bold"><a href="#i4i_section_id_5611f0ee-4722-4301-9db6-c57513251345">CLINICAL PHARMACOLOGY: Special Populations: <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></span>). </p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_992be499-2596-403f-9164-d4e2bf337055"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS </h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_532949be-1b52-4b37-8d5f-9e4d8d243b3f"></a><a name="section-6.1"></a><p></p>
<h2>General: </h2>
<p class="First">Atovaquone and proguanil hydrochloride has not been evaluated for the treatment of <span class="product-label-link" type="condition" conceptid="4202367" conceptname="Cerebral malaria">cerebral malaria</span> or other severe manifestations of complicated <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>, including hyperparasitemia, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>. Patients with severe <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> are not candidates for oral therapy. </p>
<p>Elevated liver function tests and rare cases of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> have been reported with <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> use of atovaquone and proguanil hydrochloride. A single case of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> requiring liver transplantation has also been reported with <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> use. </p>
<p>Absorption of atovaquone may be reduced in patients with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. If atovaquone and proguanil hydrochloride is used in patients who are <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (see <span class="Bold"><a href="#i4i_dosage_admin_id_11be0602-fd6d-4814-a137-2f7afc8602a4">DOSAGE AND ADMINISTRATION</a></span>), parasitemia should be closely monitored and the use of an antiemetic considered. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> occurred in up to 19% of pediatric patients given treatment doses of atovaquone and proguanil hydrochloride. In the controlled clinical trials of atovaquone and proguanil hydrochloride, 15.3% of adults who were treated with atovaquone/proguanil received an antiemetic drug during that part of the trial when they received atovaquone/proguanil. Of these patients, 98.3% were successfully treated. In patients with severe or persistent <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, alternative antimalarial therapy may be required. </p>
<p>Parasite relapse occurred commonly when <span class="Italics">P. vivax</span> <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> was treated with atovaquone and proguanil hydrochloride alone. </p>
<p>In the event of recrudescent <span class="Italics">P. falciparum</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> after treatment with atovaquone and proguanil hydrochloride or failure of chemoprophylaxis with atovaquone and proguanil hydrochloride, patients should be treated with a different blood schizonticide.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_a4900591-865b-492e-a14f-5aa07b2946bc"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients: </h2>
<p class="First">Patients should be instructed:</p>
<dl>
<dt>•</dt>
<dd>to take atovaquone and proguanil hydrochloride tablets at the same time each day with food or a milky drink.</dd>
<dt>•</dt>
<dd>to take a repeat dose of atovaquone and proguanil hydrochloride if <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> occurs within 1 hour after dosing.</dd>
<dt>•</dt>
<dd>to take a dose as soon as possible if a dose is missed, then return to their normal dosing schedule. However, if a dose is skipped, the patient should not double the next dose.</dd>
<dt>•</dt>
<dd>that rare serious adverse events such as <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, neurological, and hematological events have been reported when atovaquone and proguanil hydrochloride was used for the prophylaxis or treatment of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>.</dd>
<dt>•</dt>
<dd>to consult a healthcare professional regarding alternative forms of prophylaxis if prophylaxis with atovaquone and proguanil hydrochloride is prematurely discontinued for any reason.</dd>
<dt>•</dt>
<dd>that protective clothing, insect repellants, and bednets are important components of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> prophylaxis.</dd>
<dt>•</dt>
<dd>that no chemoprophylactic regimen is 100% effective; therefore, patients should seek medical attention for any febrile illness that occurs during or after return from a <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>-endemic area and inform their healthcare professional that they may have been exposed to <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>. </dd>
<dt>•</dt>
<dd>that <span class="product-label-link" type="condition" conceptid="438343" conceptname="Falciparum malaria">falciparum malaria</span> carries a higher risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and serious complications in pregnant women than in the general population. Pregnant women anticipating travel to malarious areas should discuss the risks and benefits of such travel with their physicians (see Pregnancy section).</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_drug_interaction_id_689f4f71-356c-43cf-9afd-9f4375ab3ac9"></a><a name="section-6.3"></a><p></p>
<h2>Drug Interactions: </h2>
<p class="First">Concomitant treatment with <span class="Bold">tetracycline</span> has been associated with approximately a 40% reduction in plasma concentrations of atovaquone. Parasitemia should be closely monitored in patients receiving tetracycline. While antiemetics may be indicated for patients receiving atovaquone and proguanil hydrochloride, <span class="Bold">metoclopramide</span> may reduce the bioavailability of atovaquone and should be used only if other antiemetics are not available.</p>
<p>Concomitant administration of <span class="Bold">rifampin</span> or <span class="Bold">rifabutin</span> is known to reduce atovaquone levels by approximately 50% and 34%, respectively. The concomitant administration of atovaquone and proguanil hydrochloride and rifampin or rifabutin is not recommended.</p>
<p>Proguanil may potentiate the anticoagulant effect of warfarin and other coumarin-based anticoagulants. The mechanism of this potential drug interaction has not been established. Caution is advised when initiating or withdrawing <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> prophylaxis or treatment with atovaquone and proguanil hydrochloride in patients on continuous treatment with coumarin-based anticoagulants. When these products are administered concomitantly, suitable coagulation tests should be closely monitored. </p>
<p>Atovaquone is highly protein bound (&gt;99%) but does not displace other highly protein-bound drugs in vitro, indicating significant drug interactions arising from displacement are unlikely. </p>
<p>Potential interactions between proguanil or cycloguanil and other drugs that are CYP2C19 substrates or inhibitors are unknown. </p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_54ce0d87-6176-4197-a21b-b373ced2f508"></a><a name="section-6.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility: </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_31964355-156f-43fd-a924-71f4c6d5281a"></a><a name="section-6.4.1"></a><p></p>
<h3>Atovaquone: </h3>
<p class="First">Carcinogenicity studies in rats were negative; 24-month studies in mice showed treatment-related increases in incidence of <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenoma</span> and hepatocellular carcinoma at all doses tested which ranged from approximately 5 to 8 times the average steady-state plasma concentrations in humans during prophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>. Atovaquone was negative with or without metabolic activation in the Ames <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span> mutagenicity assay, the Mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> mutagenesis assay, and the Cultured Human Lymphocyte cytogenetic assay. No evidence of genotoxicity was observed in the <span class="Italics">in vivo</span> Mouse Micronucleus assay.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7e041dcf-4447-470d-862b-4166dbf2c83c"></a><a name="section-6.4.2"></a><p></p>
<h3>Proguanil:   </h3>
<p class="First">No evidence of a carcinogenic effect was observed in 24-month studies conducted in CD-1 mice (doses up to 1.5 times the average systemic human exposure based on AUC) and in Wistar Hannover rats (doses up to 1.1 times the average systemic human exposure). </p>
<p>Proguanil was negative with or without metabolic activation in the Ames <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span> mutagenicity assay and the Mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> mutagenesis assay. No evidence of genotoxicity was observed in the <span class="Italics">in vivo</span> Mouse Micronucleus assay.</p>
<p>Cycloguanil, the active metabolite of proguanil, was also negative in the Ames test, but was positive in the Mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> assay and the Mouse Micronucleus assay. These positive effects with cycloguanil, a dihydrofolate reductase inhibitor, were significantly reduced or abolished with folinic acid supplementation.</p>
<p>A fertility study in Sprague-Dawley rats revealed no adverse effects at doses up to 16 mg/kg/day of proguanil hydrochloride (up to 0.2-times the average human exposure based on AUC comparisons.) Fertility studies of proguanil in animals at exposures similar to or greater than those observed in humans have not been conducted.</p>
<p>Genotoxicity studies have not been performed with atovaquone in combination with proguanil. Effects of atovaquone and proguanil hydrochloride on male and female reproductive performance are unknown.</p>
</div>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_03a20bc9-0cb7-4ef1-aa08-71cca8b01e09"></a><a name="section-6.5"></a><p></p>
<h2>Pregnancy: </h2>
<p class="First">Pregnancy Category C. <span class="product-label-link" type="condition" conceptid="438343" conceptname="Falciparum malaria">Falciparum malaria</span> carries a higher risk of morbidity and mortality in pregnant women than in the general population. Maternal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and fetal loss are both known complications of <span class="product-label-link" type="condition" conceptid="438343" conceptname="Falciparum malaria">falciparum malaria</span> in pregnancy. In pregnant women who must travel to <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>-endemic areas, personal protection against mosquito bites should always be employed (see Information for Patients) in addition to antimalarials.</p>
<p>Atovaquone was not teratogenic and did not cause reproductive toxicity in rats at maternal plasma concentrations up to 5 to 6.5 times the estimated human exposure during treatment of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>. Following single-dose administration of <span class="Sup">14</span>C-labeled atovaquone to pregnant rats, concentrations of radiolabel in rat fetuses were 18% (mid-gestation) and 60% (late gestation) of concurrent maternal plasma concentrations. In rabbits, atovaquone caused maternal toxicity at plasma concentrations that were approximately 0.6 to 1.3 times the estimated human exposure during treatment of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>. Adverse fetal effects in rabbits, including decreased fetal body lengths and increased early resorptions and post-implantation losses, were observed only in the presence of maternal toxicity. Concentrations of atovaquone in rabbit fetuses averaged 30% of the concurrent maternal plasma concentrations. </p>
<p>A pre- and post-natal study in Sprague-Dawley rats revealed no adverse effects at doses up to 16 mg/kg/day of proguanil hydrochloride (up to 0.2-times the average human exposure based on AUC comparisons.) Pre- and post-natal studies of proguanil in animals at exposures similar to or greater than those observed in humans have not been conducted.</p>
<p>The combination of atovaquone and proguanil hydrochloride was not teratogenic in rats at plasma concentrations up to 1.7 and 0.10 times, respectively, the estimated human exposure during treatment of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>. In rabbits, the combination of atovaquone and proguanil hydrochloride was not teratogenic or embryotoxic to rabbit fetuses at plasma concentrations up to 0.34 and 0.82 times, respectively, the estimated human exposure during treatment of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>. </p>
<p>While there are no adequate and well-controlled studies of atovaquone and/or proguanil hydrochloride in pregnant women, atovaquone and proguanil hydrochloride may be used if the potential benefit justifies the potential risk to the fetus. The proguanil component of atovaquone and proguanil hydrochloride acts by inhibiting the parasitic dihydrofolate reductase (see <span class="Bold"><a href="#i4i_section_id_51ead136-c2d8-4f39-a4de-93f8a8962491">CLINICAL PHARMACOLOGY: Microbiology: Mechanism of Action</a></span>). However, there are no clinical data indicating that folate supplementation diminishes drug efficacy, and for women of childbearing age receiving folate supplements to prevent neural tube <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>, such supplements may be continued while taking atovaquone and proguanil hydrochloride. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_ed69c13e-4e68-4a62-99fe-cfcd30cbdba5"></a><a name="section-6.6"></a><p></p>
<h2>Nursing Mothers: </h2>
<p class="First">It is not known whether atovaquone is excreted into human milk. In a rat study, atovaquone concentrations in the milk were 30% of the concurrent atovaquone concentrations in the maternal plasma. </p>
<p>Proguanil is excreted into human milk in small quantities.</p>
<p>Caution should be exercised when atovaquone and proguanil hydrochloride is administered to a nursing mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_105b23cd-790c-417b-8f16-ccadb5e2a6db"></a><a name="section-6.7"></a><p></p>
<h2>Pediatric Use: </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a8b06e88-f91e-4e61-beb8-6dc638021dcf"></a><a name="section-6.7.1"></a><p></p>
<h3>Treatment of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span>:</h3>
<p class="First">The efficacy and safety of atovaquone and proguanil hydrochloride for the treatment of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> have been established in controlled studies involving pediatric patients weighing 5 kg or more (see <span class="Bold"><a href="#i4i_clinical_studies_id_bd56a754-da82-4431-8a36-0e09cc96d52e">CLINICAL STUDIES</a></span>). Safety and effectiveness have not been established in pediatric patients who weigh less than 5 kg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0ab816a9-1014-4473-97c0-b177459258b7"></a><a name="section-6.7.2"></a><p></p>
<h3>Prophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span>:</h3>
<p class="First">The efficacy and safety of atovaquone and proguanil hydrochloride have been established for the prophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> in controlled studies involving pediatric patients weighing 11 kg or more (see <span class="Bold"><a href="#i4i_clinical_studies_id_bd56a754-da82-4431-8a36-0e09cc96d52e">CLINICAL STUDIES</a></span>). Safety and effectiveness have not been established in pediatric patients who weigh less than 11 kg. </p>
</div>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_bc7aa5da-ab47-498d-9f26-dae4a57b9f14"></a><a name="section-6.8"></a><p></p>
<h2>Geriatric Use: </h2>
<p class="First">Clinical studies of atovaquone and proguanil hydrochloride did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, the higher systemic exposure to cycloguanil (see <span class="Bold"><a href="#i4i_section_id_6e121914-d5b5-4f12-9361-54a76af98693">CLINICAL PHARMACOLOGY: Special Populations: Geriatrics</a></span>), and the greater frequency of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_a8f1a5d5-76bb-4f6f-9880-eca63a118795"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS </h1>
<p class="First">Because atovaquone and proguanil hydrochloride contains atovaquone and proguanil hydrochloride, the type and severity of adverse reactions associated with each of the compounds may be expected. The higher treatment doses of atovaquone and proguanil hydrochloride were less well tolerated than the lower <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> doses.</p>
<p>Among adults who received atovaquone and proguanil hydrochloride for treatment of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>, attributable adverse experiences that occurred in ≥5% of patients were <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (17%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (12%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (12%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (10%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (8%), <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> (8%), <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> (5%), and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (5%). Treatment was discontinued prematurely due to an adverse experience in 4 of 436 adults treated with atovaquone and proguanil hydrochloride.</p>
<p>Among pediatric patients (weighing 11 to 40 kg) who received atovaquone and proguanil hydrochloride for the treatment of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>, attributable adverse experiences that occurred in ≥5% of patients were <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (10%) and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (6%). <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> occurred in 43 of 319 (13%) pediatric patients who did not have symptomatic <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> but were given treatment doses of atovaquone and proguanil hydrochloride for 3 days in a clinical trial. The design of this clinical trial required that any patient who <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomited</span> be withdrawn from the trial. Among pediatric patients with symptomatic <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> treated with atovaquone and proguanil hydrochloride, treatment was discontinued prematurely due to an adverse experience in 1 of 116 (0.9%).</p>
<p>In a study of 100 pediatric patients (5 to &lt;11 kg body weight) who received atovaquone and proguanil hydrochloride for the treatment of uncomplicated <span class="Italics">P. falciparum</span> <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>, only <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (6%) occurred in ≥5% of patients as an adverse experience attributable to atovaquone and proguanil hydrochloride. In 3 patients (3%), treatment was discontinued prematurely due to an adverse experience.</p>
<p>Abnormalities in laboratory tests reported in clinical trials were limited to elevations of transaminases in <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> patients being treated with atovaquone and proguanil hydrochloride. The frequency of these abnormalities varied substantially across studies of treatment and were not observed in the randomized portions of the prophylaxis trials. </p>
<p>In one phase III trial of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> treatment in Thai adults, early elevations of ALT and AST were observed to occur more frequently in patients treated with atovaquone and proguanil hydrochloride compared to patients treated with an active control drug. Rates for patients who had normal baseline levels of these clinical laboratory parameters were: Day 7: ALT 26.7% vs. 15.6%; AST 16.9% vs. 8.6%. By day 14 of this 28-day study, the frequency of transaminase elevations equalized across the 2 groups.</p>
<p>In this and other studies in which transaminase elevations occurred, they were noted to persist for up to 4 weeks following treatment with atovaquone and proguanil hydrochloride for <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>. None were associated with untoward clinical events.</p>
<p>Among subjects who received atovaquone and proguanil hydrochloride for prophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> in placebo-controlled trials, adverse experiences occurred in similar proportions of subjects receiving atovaquone and proguanil hydrochloride or placebo (Table 3). The most commonly reported adverse experiences possibly attributable to atovaquone and proguanil hydrochloride or placebo were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>. Prophylaxis with atovaquone and proguanil hydrochloride was discontinued prematurely due to a treatment-related adverse experience in 3 of 381 adults and 0 of 125 pediatric patients.</p>
<a name="_RefID4376E6CC06414BE5BD9C12379370D63D"></a><table>
<caption><span>Table 3. Adverse Experiences in Placebo-Controlled Clinical Trials of Atovaquone and Proguanil hydrochloride for Prophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span> </span></caption>
<col width="15%">
<col width="11%">
<col width="21%">
<col width="21%">
<col width="11%">
<col width="21%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="5"><p class="First">Percent of Subjects With Adverse Experiences (Percent of Subjects With Adverse Experiences Attributable to Therapy) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2"><p class="First">Adverse Experience</p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="3"><p class="First">Adults </p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2"><p class="First">Children and Adolescents </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Placebo n=206</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Atovaquone and Proguanil hydrochloride n=206</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Atovaquone and Proguanil hydrochloride n=381</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Placebo n=140</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Atovaquone and Proguanil hydrochloride n=125</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">27 (7)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">22 (3)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">17 (5)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">21 (14)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">19 (14)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">13 (1)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">5 (0)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">3 (0)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">11 (&lt;1)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">6 (0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">11 (0)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">12 (0)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">7 (0)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0 (0)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0 (0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">10 (5)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">9 (4)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">6 (3)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">29 (29)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">33 (31)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">8 (&lt;1)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">6 (&lt;1)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">4 (1)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">9 (0)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">9 (0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">8 (3)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">6 (2)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">4 (1)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">3 (1)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">2 (0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory infection</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">7 (0)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">8 (0)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">5 (0)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0 (0)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">&lt;1 (0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">5 (4)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">3 (2)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">2 (1)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0 (0)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0 (0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">4 (0)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">8 (0)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">4 (0)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0 (0)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0 (0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">Gastritis</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">3 (2)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">3 (3)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">2 (2)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0 (0)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0 (0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">2 (&lt;1)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">1 (&lt;1)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">&lt;1 (&lt;1)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">6 (6)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">7 (7)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Flu syndrome</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">1 (0)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">2 (0)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">4 (0)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">6 (0)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">9 (0)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">Any adverse experience</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">65 (32)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">54 (17)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">49 (17)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">62 (41)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">60 (42)</p></td>
</tr>
</tbody>
</table>
<p>In an additional placebo-controlled study of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> prophylaxis with atovaquone and proguanil hydrochloride involving 330 pediatric patients in a <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>-endemic area (see <span class="Bold"><a href="#i4i_clinical_studies_id_bd56a754-da82-4431-8a36-0e09cc96d52e">CLINICAL STUDIES</a></span>), the safety profile of atovaquone and proguanil hydrochloride was consistent with that described above. The most common treatment-emergent adverse events with atovaquone and proguanil hydrochloride were <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (13%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (13%), and <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> (10%). <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> (13% vs. 8%) and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (5% vs. 3%) were reported more often with atovaquone and proguanil hydrochloride than with placebo, while <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (5% vs. 12%) and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (1% vs. 5%) were more common with placebo. No patient withdrew from the study due to an adverse experience with atovaquone and proguanil hydrochloride. No routine laboratory data were obtained during this study.</p>
<p>Among subjects who received atovaquone and proguanil hydrochloride for prophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> in clinical trials with an active comparator, adverse experiences occurred in a similar or lower proportion of subjects receiving atovaquone and proguanil hydrochloride than an active comparator (Table 4). The mean durations of dosing and the periods for which the adverse experiences are summarized in Table 4, were 28 days (Study 1) and 26 days (Study 2) for atovaquone and proguanil hydrochloride, 53 days for mefloquine, and 49 days for chloroquine plus proguanil (reflecting the different recommended dosing regimens). Fewer neuropsychiatric adverse experiences occurred in subjects who received atovaquone and proguanil hydrochloride than mefloquine. Fewer gastrointestinal adverse experiences occurred in subjects receiving atovaquone and proguanil hydrochloride than chloroquine/proguanil. Compared with active comparator drugs, subjects receiving atovaquone and proguanil hydrochloride had fewer adverse experiences overall that were attributed to <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> therapy (Table 4). Prophylaxis with atovaquone and proguanil hydrochloride was discontinued prematurely due to a treatment-related adverse experience in 7 of 1,004 travelers.</p>
<a name="_RefID7917DBADD339494A81965F6D40D79DED"></a><table>
<caption><span>Table 4. Adverse Experiences in Active-Controlled Clinical Trials of Atovaquone and Proguanil hydrochloride for Prophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span> </span></caption>
<col width="20%">
<col width="23%">
<col width="15%">
<col width="23%">
<col width="19%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="11" valign="top">* Adverse experiences that started while receiving active study drug.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="4"><p class="First">Percent of Subjects With Adverse Experiences (Percent of Subjects With Adverse Experiences Attributable to Therapy) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" colspan="2"><p class="First">Study 1 </p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2"><p class="First">Study 2 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Adverse Experience</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Atovaquone and Proguanil hydrochloride n=493</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Mefloquine n=483</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Atovaquone and Proguanil hydrochloride n=511</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Chloroquine Plus Proguanil n=511</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">38 (8)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">36 (7)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">34 (5)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">39 (7)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">14 (3)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">20 (8)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">11 (2)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">18 (7)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">17 (5)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">16 (5)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">14 (3)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">22 (6)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">12 (4)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">17 (7)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">12 (4)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">14 (4)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Dreams</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">7 (7)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">16 (14)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">6 (4)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">7 (3)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">5 (3)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">16 (13)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">4 (2)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">5 (2)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">9 (&lt;1)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">11 (1)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">8 (&lt;1)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">8 (&lt;1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">5 (2)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">14 (9)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">7 (3)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">8 (4)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">8 (1)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">10 (2)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">8 (0)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">14 (2)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Oral <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">9 (6)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">6 (4)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">5 (4)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">7 (5)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">4 (2)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">5 (2)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">3 (1)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">2 (&lt;1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Visual difficulties</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">2 (2)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">5 (3)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">3 (2)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">3 (2)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">&lt;1 (&lt;1)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">5 (4)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">&lt;1 (&lt;1)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">1 (&lt;1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">1 (&lt;1)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">5 (4)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">&lt;1 (&lt;1)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">1 (&lt;1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Any adverse experience</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">64 (30)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">69 (42)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">58 (22)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">66 (28)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Any neuropsychiatric event</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">20 (14)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">37 (29)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">16 (10)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">20 (10)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">Any GI event</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">49 (16)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">50 (19)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">43 (12)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">54 (20)</p></td>
</tr>
</tbody>
</table>
<p>In a third active-controlled study, atovaquone and proguanil hydrochloride (n = 110) was compared with chloroquine/proguanil (n = 111) for the prophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> in 221 non-immune pediatric patients (see <span class="Bold"><a href="#i4i_clinical_studies_id_bd56a754-da82-4431-8a36-0e09cc96d52e">CLINICAL STUDIES</a></span>). The mean duration of exposure was 23 days for atovaquone and proguanil hydrochloride, 46 days for chloroquine, and 43 days for proguanil, reflecting the different recommended dosage regimens for these products. Fewer patients treated with atovaquone and proguanil hydrochloride reported <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (2% vs. 7%) or <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (&lt;1% vs. 7%) than children who received chloroquine/proguanil. <span class="product-label-link" type="condition" conceptid="4260546" conceptname="Ulcerative stomatitis">Oral ulceration</span> (2% vs. 2%), <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">vivid dreams</span> (2% vs. &lt;1%), and <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> (0% vs. 2%) occurred in similar proportions of patients receiving either atovaquone and proguanil hydrochloride or chloroquine/proguanil, respectively. Two patients discontinued prophylaxis with chloroquine/proguanil due to adverse events, while none of those receiving atovaquone and proguanil hydrochloride discontinued due to adverse events. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_05e713fe-b240-4188-9075-0fcc21ec03aa"></a><a name="section-7.1"></a><p></p>
<h2>Post-Marketing Adverse Reactions:</h2>
<p class="First">In addition to adverse events reported from clinical trials, the following events have been identified during world-wide post-approval use of atovaquone and proguanil hydrochloride. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to atovaquone and proguanil hydrochloride. </p>
<p><span class="Bold"><span class="Italics">Blood and Lymphatic System Disorders:</span></span> <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> and rarely <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">Pancytopenia</span> in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> treated with proguanil.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>:</span></span><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and rare cases of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>. </p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:</span></span> Rare cases of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> events (such as <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>); however, a causal relationship has not been established. </p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>: </span></span><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span>.</p>
<p><span class="Bold"><span class="Italics">Hepatobiliary Disorders:</span></span> Elevated liver function tests and rare cases of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>; a single case of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, cholestatis; failure requiring transplant has been reported.</p>
<p><span class="Bold"><span class="Italics">Skin and Subcutaneous Tissue Disorders:</span></span> <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and rare cases of <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> and <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_7ebdf3ed-ed5e-4138-9ea5-5984649de9bc"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE </h1>
<p class="First">There is no information on <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of atovaquone and proguanil hydrochloride substantially higher than the doses recommended for treatment.</p>
<p>There is no known antidote for atovaquone, and it is currently unknown if atovaquone is dialyzable. The median lethal dose is higher than the maximum oral dose tested in mice and rats (1,825 mg/kg/day). <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdoses</span> up to 31,500 mg of atovaquone have been reported. In one such patient who also took an unspecified dose of dapsone, <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> occurred. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> has also been reported after <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdoses</span> of proguanil hydrochloride as large as 1,500 mg have been followed by complete recovery, and doses as high as 700 mg twice daily have been taken for over 2 weeks without serious toxicity. Adverse experiences occasionally associated with proguanil hydrochloride doses of 100 to 200 mg/day, such as epigastria <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> would be likely to occur with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. There are also reports of reversible <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span> and scaling of the skin on the palms and/or soles, reversible aphthous ulceration, and hematologic side effects.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_11be0602-fd6d-4814-a137-2f7afc8602a4"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION </h1>
<p class="First">The daily dose should be taken at the same time each day with food or a milky drink. In the event of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> within 1 hour after dosing, a repeat dose should be taken.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_020e4823-4546-4f56-98f4-a589aa50c256"></a><a name="section-9.1"></a><p></p>
<h2>Prevention of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span>:</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> treatment with atovaquone and proguanil hydrochloride should be started 1 or 2 days before entering a <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>-endemic area and continued daily during the stay and for 7 days after return. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bbdf882f-1673-4531-8b90-87562006f6ab"></a><a name="section-9.1.1"></a><p></p>
<h3>Adults:  </h3>
<p class="First">One atovaquone and proguanil hydrochloride tablet (adult strength = 250 mg atovaquone/100 mg proguanil hydrochloride) per day. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_25dc029d-87f6-4c30-a051-4740139e7e0c"></a><a name="section-9.2"></a><p></p>
<h2>Treatment of Acute <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span>: </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d319d442-ac80-4f48-ac57-8034900b9303"></a><a name="section-9.2.1"></a><p></p>
<h3>Adults:  </h3>
<p class="First">Four Atovaquone and proguanil hydrochloride tablets (adult strength; total daily dose 1 g atovaquone/400 mg proguanil hydrochloride) as a single dose daily for 3 consecutive days. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_290658df-f0d1-4fc7-ac70-20a9630edce3"></a><a name="section-9.3"></a><p></p>
<h2>Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</h2>
<p class="First">Atovaquone and proguanil hydrochloride tablet should not be used for <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> prophylaxis in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance &lt;30 mL/min). Atovaquone and proguanil hydrochloride tablet may be used with caution for the treatment of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance &lt;30 mL/min), only if the benefits of the 3-day treatment regimen outweigh the potential risks associated with increased drug exposure (see <span class="Bold"><a href="#i4i_section_id_5611f0ee-4722-4301-9db6-c57513251345">CLINICAL PHARMACOLOGY: Special Populations: <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></span>). No dosage adjustments are needed in patients with mild (creatinine clearance 50 to 80 mL/min) and moderate (creatinine clearance 30 to 50 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (see <span class="Bold"><a href="#i4i_section_id_80121c9e-1582-4ded-932f-789aa6d7d1da">CLINICAL PHARMACOLOGY: Special Populations</a></span>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f1803bb3-87fb-4deb-b784-29585b005a9e"></a><a name="section-9.4"></a><p></p>
<h2>Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</h2>
<p class="First">No dosage adjustments are needed in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. No studies have been conducted in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (see <span class="Bold"><a href="#i4i_section_id_f413b338-49cf-4fdf-8bd9-55ad2fd8a215">CLINICAL PHARMACOLOGY: Special Populations: <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></span>). </p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_d5b28391-5d0d-4e34-958e-db1379ca4c25"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED </h1>
<p class="First">Atovaquone and proguanil hydrochloride tablets, containing 250 mg atovaquone and 100 mg proguanil hydrochloride, are pinkish brown to brown colored, circular, biconvex beveled edge, film-coated tablets with ‘404’ debossed on one side and ‘G’ debossed on the other side. </p>
<p>Atovaquone and proguanil hydrochloride tablets 250 mg/100 mg</p>
<p><br>NDC 54868-6393-0 unit dose pack of 24</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_b570eb2d-605b-423f-926e-a03428439c77"></a><a name="section-11"></a><p></p>
<p class="First"><span class="Bold">Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) (see USP Controlled Room Temperature)</span>.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="i4i_animal_pharmacology_id_00a41709-8a60-4bce-a2dd-cf50c6c99888"></a><a name="section-12"></a><p></p>
<h1>ANIMAL TOXICOLOGY </h1>
<p class="First">Fibrovascular proliferation in the right atrium, <span class="product-label-link" type="condition" conceptid="198199" conceptname="Pyelonephritis">pyelonephritis</span>, bone marrow hypocellularity, lymphoid <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, and <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>/<span class="product-label-link" type="condition" conceptid="201773" conceptname="Enteritis of small intestine">enteritis</span> were observed in dogs treated with proguanil hydrochloride for 6 months at a dose of 12 mg/kg/day (approximately 3.9 times the recommended daily human dose for <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> prophylaxis on a mg/m<span class="Sup">2</span> basis). Bile duct <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>, gall bladder mucosal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, and <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonia</span> were observed in dogs treated with proguanil hydrochloride for 6 months at a dose of 4 mg/kg/day (approximately 1.3 times the recommended daily human dose for <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> prophylaxis on a mg/m<span class="Sup">2</span> basis). Mucosal <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> of the cecum and renal tubular <span class="product-label-link" type="condition" conceptid="314617" conceptname="Basophilia">basophilia</span> were observed in rats treated with proguanil hydrochloride for 6 months at a dose of 20 mg/kg/day (approximately 1.6 times the recommended daily human dose for <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> prophylaxis on a mg/m<span class="Sup">2</span> basis). Adverse heart, lung, liver, and gall bladder effects observed in dogs and kidney effects observed in rats were not shown to be reversible. </p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_bd56a754-da82-4431-8a36-0e09cc96d52e"></a><a name="section-13"></a><p></p>
<h1>CLINICAL STUDIES </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bcc3b6ee-3ef5-48dc-bcbf-40811728bf52"></a><a name="section-13.1"></a><p></p>
<h2>Treatment of Acute Malarial <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>:</h2>
<p class="First">In 3 phase II clinical trials, atovaquone alone, proguanil hydrochloride alone, and the combination of atovaquone and proguanil hydrochloride were evaluated for the treatment of acute, uncomplicated <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> caused by <span class="Italics">P. falciparum</span>. Among 156 evaluable patients, the parasitological cure rate was 59/89 (66%) with atovaquone alone, 1/17 (6%) with proguanil hydrochloride alone, and 50/50 (100%) with the combination of atovaquone and proguanil hydrochloride. </p>
<p>Atovaquone and proguanil hydrochloride was evaluated for treatment of acute, uncomplicated <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> caused by <span class="Italics">P. falciparum</span> in 8 phase III controlled clinical trials. Among 471 evaluable patients treated with the equivalent of 4 atovaquone and proguanil hydrochloride tablets once daily for 3 days, 464 had a sensitive response (elimination of parasitemia with no recurrent parasitemia during follow-up for 28 days) (see Table 5). Seven patients had a response of RI resistance (elimination of parasitemia but with recurrent parasitemia between 7 and 28 days after starting treatment). In these trials, the response to treatment with atovaquone and proguanil hydrochloride was similar to treatment with the comparator drug in 4 trials, and better than the response to treatment with the comparator drug in the other 4 trials. </p>
<p>The overall efficacy in 521 evaluable patients was 98.7% (Table 5).</p>
<a name="_RefIDA118834467E2423B912372BF200B8E91"></a><table>
<caption><span>Table 5. Parasitological Response in Clinical Trials of Atovaquone and Proguanil hydrochloride for Treatment of P. <span class="product-label-link" type="condition" conceptid="438343" conceptname="Falciparum malaria">falciparum Malaria</span> </span></caption>
<col width="12%">
<col width="15%">
<col width="15%">
<col width="29%">
<col width="15%">
<col width="15%">
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Elimination of parasitemia with no recurrent parasitemia during follow-up for 28 days.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">†</a></dt>
<dd>Patients hospitalized only for acute care. Follow-up conducted in outpatients.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2"><p class="First">Atovaquone and proguanil hydrochloride
                                    </p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="3"><p class="First">Comparator </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Study Site</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Evaluable Patients (n)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">% Sensitive Response<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Drug (s)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Evaluable Patients (n)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">% Sensitive Response<a href="#footnote-3" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Brazil</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">74</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">98.6%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Quinine and tetracycline</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">76</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">100.0%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Thailand</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">79</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">100.0%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Mefloquine</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">79</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">86.1%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">France<a name="footnote-reference-4" href="#footnote-4" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">21</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">100.0%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Halofantrine</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">18</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">100.0%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Kenya<a href="#footnote-4" class="Sup">†</a>,
                                    </p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">81</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">93.8%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Halofantrine</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">83</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">90.4%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Zambia</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">80</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">100.0%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Pyrimethamine/sulfadoxine (P/S)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">80</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">98.8%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Gabon<a href="#footnote-4" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">63</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">98.4%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Amodiaquine</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">63</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">81.0%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Phillipines</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">54</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">100.0%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Chloroquine (C/q) <br>Cq and P/S</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">23<br> 32</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">30.4%<br> 87.5%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">Peru</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">19</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">100.0%</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Chloroquine <br>P/S</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">13<br> 7</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">7.7%<br> 100.0%</p></td>
</tr>
</tbody>
</table>
<p>Eighteen of 521 (3.5%) evaluable patients with acute <span class="product-label-link" type="condition" conceptid="438343" conceptname="Falciparum malaria">falciparum malaria</span> presented with a pretreatment serum creatinine greater than 2.0 mg/dL (range 2.1 to 4.3 mg/dL). All were successfully treated with atovaquone and proguanil hydrochloride and 17 of 18 (94.4%) had normal serum creatinine levels by day 7. </p>
<p>Data from a phase II trial of atovaquone conducted in Zambia suggested that approximately 40% of the study population in this country were HIV-infected patients. The enrollment criteria were similar for the phase III trial of atovaquone and proguanil hydrochloride conducted in Zambia and the results are presented in Table 5. Efficacy rates for atovaquone and proguanil hydrochloride in this study population were high and comparable to other populations studied.</p>
<p>The efficacy of atovaquone and proguanil hydrochloride in the treatment of the erythrocytic phase of nonfalciparum <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> was assessed in a small number of patients. Of the 23 patients in Thailand infected with <span class="Italics">P. vivax</span> and treated with atovaquone/proguanil hydrochloride 1,000 mg/400 mg daily for 3 days, parasitemia cleared in 21 (91.3%) at 7 days. Parasite relapse occurred commonly when <span class="Italics">P. vivax</span> <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> was treated with atovaquone and proguanil hydrochloride alone. Seven patients in Gabon with <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> due to <span class="Italics">P. ovale</span> or <span class="Italics">P. malariae</span> were treated with atovaquone/proguanil hydrochloride 1,000 mg/400 mg daily for 3 days. All 6 evaluable patients (3 with <span class="Italics">P. malariae</span>, 2 with <span class="Italics">P. ovale</span>, and 1 with mixed <span class="Italics">P. falciparum</span> and <span class="Italics">P. ovale</span>) were cured at 28 days. Relapsing <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malarias</span> including <span class="Italics">P. vivax</span> and <span class="Italics">P. ovale</span> require additional treatment to prevent relapse.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d85708ae-65ea-4607-8515-2a54430ceda0"></a><a name="section-13.2"></a><p></p>
<h2>Prevention of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span>:</h2>
<p class="First">Atovaquone and proguanil hydrochloride was evaluated for prophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> in 5 clinical trials in <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>-endemic areas and in 3 active-controlled trials in non-immune travelers to <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>-endemic areas.</p>
<p>Three placebo-controlled studies of 10 to 12 weeks' duration were conducted among residents of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>-endemic areas in Kenya, Zambia, and Gabon. Of a total of 669 randomized patients (including 264 pediatric patients 5 to 16 years of age), 103 were withdrawn for reasons other than <span class="product-label-link" type="condition" conceptid="438343" conceptname="Falciparum malaria">falciparum malaria</span> or drug-related adverse events. (Fifty-five percent of these were lost to follow-up and 45% were withdrawal for protocol violations). The results are listed in Table 6.</p>
<a name="_RefID6423B8CF0CE34F7AB85CE128B446165A"></a><table>
<caption><span>Table 6. Prevention of Parasitemia in Placebo-Controlled Clinical Trials of Atovaquone and Proguanil hydrochloride for Prophylaxis of P. <span class="product-label-link" type="condition" conceptid="438343" conceptname="Falciparum malaria">falciparum Malaria</span> in Residents of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span>-Endemic Areas </span></caption>
<col width="44%">
<col width="46%">
<col width="11%">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Toprule"><p class="First"> </p></td>
<td class="Lrule Toprule"><p class="First">Atovaquone and proguanil hydrochloride</p></td>
<td class="Toprule"><p class="First">Placebo</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">Total number of patients randomized</p></td>
<td class="Lrule"><p class="First">326</p></td>
<td><p class="First">341</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">Failed to complete study</p></td>
<td class="Lrule"><p class="First">57</p></td>
<td><p class="First">44</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">Developed parasitemia (<span class="Italics">P. falciparum</span>)</p></td>
<td class="Botrule Lrule"><p class="First">2</p></td>
<td class="Botrule"><p class="First">92</p></td>
</tr>
</tbody>
</table>
<p>In another study, 330 Gabonese pediatric patients (weighing 13 to 40 kg, and aged 4 to 14 years) who had received successful open-label radical cure treatment with artesunate, were randomized to receive either atovaquone and proguanil hydrochloride (dosage based on body weight) or placebo in a double-blind fashion for 12 weeks. Blood smears were obtained weekly and any time <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> was suspected. Nineteen of the 165 children given atovaquone and proguanil hydrochloride and 18 of 165 patients given placebo withdrew from the study for reasons other than parasitemia (primary reason was lost to follow-up). In the per-protocol population, 1 out of 150 patients (&lt;1%) who received atovaquone and proguanil hydrochloride developed <span class="Italics">P. falciparum</span> parasitemia while receiving prophylaxis with atovaquone and proguanil hydrochloride compared with 31 (22%) of the 144 placebo recipients.</p>
<p>In a 10-week study in 175 South African subjects who moved into <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>-endemic areas and were given prophylaxis with 1 atovaquone and proguanil hydrochloride daily, parasitemia developed in 1 subject who missed several doses of medication. Since no placebo control was included, the incidence of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> in this study was not known. </p>
<p>Two active-controlled studies were conducted in non-immune travelers who visited a <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>-endemic area. The mean duration of travel was 18 days (range 2 to 38 days). Of a total of 1,998 randomized patients who received atovaquone and proguanil hydrochloride or controlled drug, 24 discontinued from the study before follow-up evaluation 60 days after leaving the endemic area. Nine of these were lost to follow-up, 2 withdrew because of an adverse experience, and 13 were discontinued for other reasons. These studies were not large enough to allow for statements of comparative efficacy. In addition, the true exposure rate to <span class="Italics">P. falciparum</span> <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> in both studies is unknown. The results are listed in Table 7. </p>
<a name="_RefIDE32C98EA6A6D4030BBF279D450BF746C"></a><table>
<caption><span>Table 7. Prevention of Parasitemia in Active-Controlled Clinical Trials of Atovaquone and Proguanil hydrochloride for Prophylaxis of P. <span class="product-label-link" type="condition" conceptid="438343" conceptname="Falciparum malaria">falciparum Malaria</span> in Non-Immune Travelers </span></caption>
<col width="38%">
<col width="29%">
<col width="13%">
<col width="21%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Atovaquone and Proguanil hydrochloride</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Mefloquine</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">Chloroquine Plus Proguanil</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Total number of randomized patients who received study drug</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">1,004</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">483</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">511</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Failed to complete study</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">14</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">4</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">Developed parasitemia (<span class="Italics">P. falciparum</span>)</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First">3</p></td>
</tr>
</tbody>
</table>
<p>A third randomized, open-label study was conducted which included 221 otherwise healthy pediatric patients (weighing ≥11 kg and 2 to 17 years of age) who were at risk of contracting <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> by traveling to an endemic area. The mean duration of travel was 15 days (range 1 to 30 days). Prophylaxis with atovaquone and proguanil hydrochloride (n = 110, dosage based on body weight) began 1 or 2 days before entering the endemic area and lasted until 7 days after leaving the area. A control group (n = 111) received prophylaxis with chloroquine/proguanil dosed according to WHO guidelines. No cases of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> occurred in either group of children. However, the study was not large enough to allow for statements of comparative efficacy. In addition, the true exposure rate to <span class="Italics">P. falciparum</span> <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> in this study is unknown.</p>
<p>In a <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> challenge study conducted in healthy US volunteers, atovaquone alone prevented <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> in 6 of 6 individuals, whereas 4 of 4 placebo-treated volunteers developed <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_74a7d874-469d-4c5c-90b2-5ca2fc2a0669"></a><a name="section-13.2.1"></a><p></p>
<h3>Causal Prophylaxis: </h3>
<p class="First">In separate studies with small numbers of volunteers, atovaquone and proguanil hydrochloride were independently shown to have causal <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> activity directed against liver-stage parasites of <span class="Italics">P. falciparum</span>. Six patients given a single dose of atovaquone 250 mg 24 hours prior to <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> challenge were protected from developing <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>, whereas all 4 placebo-treated patients developed <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>. </p>
<p>During the 4 weeks following cessation of prophylaxis in clinical trial participants who remained in <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>-endemic areas and were available for evaluation, <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> developed in 24 of 211 (11.4%) subjects who took placebo and 9 of 328 (2.7%) who took atovaquone and proguanil hydrochloride . While new <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> could not be distinguished from recrudescent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, all but 1 of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in patients treated with atovaquone and proguanil hydrochloride occurred more than 15 days after stopping therapy, probably representing new <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. The single case occurring on day 8 following cessation of therapy with atovaquone and proguanil hydrochloride probably represents a failure of prophylaxis with atovaquone and proguanil hydrochloride. </p>
<p>The possibility that delayed cases of <span class="Italics">P. falciparum</span> <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> may occur some time after stopping prophylaxis with atovaquone and proguanil hydrochloride cannot be ruled out. Hence, returning travelers developing febrile illnesses should be investigated for <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9eb71a2a-0c64-44b6-9e0c-768a9bc9acff"></a><a name="section-14"></a><p></p>
<p class="First">Manufactured by:</p>
<p><span class="Bold">Glenmark Generics Ltd.</span><br>Colvale-Bardez, Goa 403 513, India</p>
<p>Manufactured for:</p>
<div class="Figure">
<a name="id11251611"></a><img alt="Glenmark logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c50d51ab-23c2-45cb-8f68-08f3454fb59b&amp;name=b876b25a-ab9b-4e58-95a8-3edc2a3ee69a-03.jpg">
</div>
<p><span class="Bold">Glenmark Generics Inc., USA</span><br>Mahwah, NJ 07430</p>
<p>Questions? 1 (888)721-7115<br>www.glenmarkgenerics.com</p>
<p>January 2011</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold">DISTRIBUTED BY:</span><br>Physicians Total Care, Inc.<br>Tulsa, OK      74146<br></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_8d34fcf4-8358-42dc-9578-3aa750811b79"></a><a name="section-15"></a><p></p>
<h1>Carton-label</h1>
<div class="Figure">
<a name="id1132"></a><img alt="Carton label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c50d51ab-23c2-45cb-8f68-08f3454fb59b&amp;name=54868-6393-0.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ATOVAQUONE AND PROGUANIL HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">atovaquone and proguanil hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6393(NDC:68462-404)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ATOVAQUONE</strong> (ATOVAQUONE) </td>
<td class="formItem">ATOVAQUONE</td>
<td class="formItem">250 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>PROGUANIL HYDROCHLORIDE</strong> (PROGUANIL) </td>
<td class="formItem">PROGUANIL HYDROCHLORIDE</td>
<td class="formItem">100 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLOXAMER 188</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE K30</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 8000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK (pinkish brown to brown) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (circular, biconvex, beveled edge) </td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">404;G</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-6393-0</td>
<td class="formItem">2  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">12  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091211</td>
<td class="formItem">01/23/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel(54868-6393)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>2deac9e5-a087-4ffc-a615-971a10d22ca5</div>
<div>Set id: c50d51ab-23c2-45cb-8f68-08f3454fb59b</div>
<div>Version: 1</div>
<div>Effective Time: 20130212</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
